S&P 500   3,376.78 (+1.29%)
DOW   27,925.88 (+0.86%)
QQQ   270.87 (+2.14%)
AAPL   446.95 (+2.16%)
MSFT   207.45 (+2.00%)
FB   262.07 (+2.32%)
GOOGL   1,505.47 (+1.68%)
AMZN   3,143.01 (+2.02%)
NVDA   450.14 (+3.72%)
CGC   17.19 (+1.42%)
BABA   253.43 (+2.02%)
TSLA   1,498.63 (+9.04%)
GE   6.66 (-1.04%)
MU   47.99 (+0.48%)
AMD   80.84 (+5.15%)
T   30.23 (+0.10%)
F   7.17 (-0.83%)
ACB   9.90 (-1.20%)
GILD   68.81 (+1.04%)
NFLX   477.27 (+2.21%)
DIS   132.06 (+1.20%)
BAC   27.03 (+0.41%)
BA   178.35 (-0.99%)
S&P 500   3,376.78 (+1.29%)
DOW   27,925.88 (+0.86%)
QQQ   270.87 (+2.14%)
AAPL   446.95 (+2.16%)
MSFT   207.45 (+2.00%)
FB   262.07 (+2.32%)
GOOGL   1,505.47 (+1.68%)
AMZN   3,143.01 (+2.02%)
NVDA   450.14 (+3.72%)
CGC   17.19 (+1.42%)
BABA   253.43 (+2.02%)
TSLA   1,498.63 (+9.04%)
GE   6.66 (-1.04%)
MU   47.99 (+0.48%)
AMD   80.84 (+5.15%)
T   30.23 (+0.10%)
F   7.17 (-0.83%)
ACB   9.90 (-1.20%)
GILD   68.81 (+1.04%)
NFLX   477.27 (+2.21%)
DIS   132.06 (+1.20%)
BAC   27.03 (+0.41%)
BA   178.35 (-0.99%)
S&P 500   3,376.78 (+1.29%)
DOW   27,925.88 (+0.86%)
QQQ   270.87 (+2.14%)
AAPL   446.95 (+2.16%)
MSFT   207.45 (+2.00%)
FB   262.07 (+2.32%)
GOOGL   1,505.47 (+1.68%)
AMZN   3,143.01 (+2.02%)
NVDA   450.14 (+3.72%)
CGC   17.19 (+1.42%)
BABA   253.43 (+2.02%)
TSLA   1,498.63 (+9.04%)
GE   6.66 (-1.04%)
MU   47.99 (+0.48%)
AMD   80.84 (+5.15%)
T   30.23 (+0.10%)
F   7.17 (-0.83%)
ACB   9.90 (-1.20%)
GILD   68.81 (+1.04%)
NFLX   477.27 (+2.21%)
DIS   132.06 (+1.20%)
BAC   27.03 (+0.41%)
BA   178.35 (-0.99%)
S&P 500   3,376.78 (+1.29%)
DOW   27,925.88 (+0.86%)
QQQ   270.87 (+2.14%)
AAPL   446.95 (+2.16%)
MSFT   207.45 (+2.00%)
FB   262.07 (+2.32%)
GOOGL   1,505.47 (+1.68%)
AMZN   3,143.01 (+2.02%)
NVDA   450.14 (+3.72%)
CGC   17.19 (+1.42%)
BABA   253.43 (+2.02%)
TSLA   1,498.63 (+9.04%)
GE   6.66 (-1.04%)
MU   47.99 (+0.48%)
AMD   80.84 (+5.15%)
T   30.23 (+0.10%)
F   7.17 (-0.83%)
ACB   9.90 (-1.20%)
GILD   68.81 (+1.04%)
NFLX   477.27 (+2.21%)
DIS   132.06 (+1.20%)
BAC   27.03 (+0.41%)
BA   178.35 (-0.99%)
Log in

NASDAQ:CNMDCONMED Stock Price, Forecast & News

$86.15
+0.21 (+0.24 %)
(As of 08/12/2020 10:50 AM ET)
Add
Compare
Today's Range
$85.97
Now: $86.15
$86.85
50-Day Range
$66.62
MA: $77.19
$87.34
52-Week Range
$37.66
Now: $86.15
$116.81
Volume1,027 shs
Average Volume409,881 shs
Market Capitalization$2.46 billion
P/E Ratio90.68
Dividend Yield0.93%
Beta0.56
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and VCARE uterine manipulator for enhancing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers endoscopic technologies offering, including diagnostic and therapeutic products for use in gastroenterology procedures; cardiology and critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company markets its products directly to surgeons, hospitals, surgery centers, group purchasing organizations, integrated delivery networks, and other customers, as well as through medical specialty distributors. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.
Read More
CONMED logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:CNMD
CUSIP20741010
Phone315-797-8375

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$955.10 million
Cash Flow$3.76 per share
Book Value$23.54 per share

Profitability

Net Income$28.62 million

Miscellaneous

Employees3,100
Market Cap$2.46 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$86.15
+0.21 (+0.24 %)
(As of 08/12/2020 10:50 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CONMED (NASDAQ:CNMD) Frequently Asked Questions

How has CONMED's stock been impacted by COVID-19 (Coronavirus)?

CONMED's stock was trading at $78.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CNMD shares have increased by 9.4% and is now trading at $86.15.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of CONMED?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CONMED
.

When is CONMED's next earnings date?

CONMED is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for CONMED
.

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) issued its quarterly earnings results on Wednesday, July, 29th. The medical technology company reported ($0.07) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.95) by $0.88. The medical technology company earned $157.80 million during the quarter, compared to analysts' expectations of $126.59 million. CONMED had a return on equity of 11.18% and a net margin of 3.00%. The firm's revenue for the quarter was down 33.8% on a year-over-year basis. During the same quarter last year, the business posted $0.56 EPS.
View CONMED's earnings history
.

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED declared a quarterly dividend on Friday, May 22nd. Stockholders of record on Monday, June 15th will be given a dividend of $0.20 per share on Monday, July 6th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.93%. The ex-dividend date of this dividend is Friday, June 12th.
View CONMED's dividend history
.

What price target have analysts set for CNMD?

7 analysts have issued 1 year price targets for CONMED's shares. Their forecasts range from $76.00 to $115.00. On average, they expect CONMED's stock price to reach $99.71 in the next year. This suggests a possible upside of 15.7% from the stock's current price.
View analysts' price targets for CONMED
.

Has CONMED been receiving favorable news coverage?

Media headlines about CNMD stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CONMED earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news stories about the medical technology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about CONMED
.

Are investors shorting CONMED?

CONMED saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 847,000 shares, a decline of 17.0% from the December 31st total of 1,020,000 shares. Based on an average daily trading volume, of 257,700 shares, the short-interest ratio is presently 3.3 days. Currently, 3.0% of the shares of the company are short sold.
View CONMED's Short Interest
.

Who are some of CONMED's key competitors?

What other stocks do shareholders of CONMED own?

Who are CONMED's key executives?

CONMED's management team includes the following people:
  • Mr. Curt R. Hartman, CEO, Pres & Director (Age 55)
  • Mr. Todd W. Garner, Exec. VP & CFO (Age 50)
  • Mr. Patrick J. Beyer, Pres of CONMED International (Age 53)
  • Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 44)
  • Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 44)

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

Who are CONMED's major shareholders?

CONMED's stock is owned by many different retail and institutional investors. Top institutional shareholders include Principal Financial Group Inc. (3.59%), Macquarie Group Ltd. (2.59%), Ceredex Value Advisors LLC (1.14%), Fisher Asset Management LLC (1.12%), Victory Capital Management Inc. (0.63%) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.46%). Company insiders that own CONMED stock include Daniel Jonas, Dirk Kuyper, Heather L Cohen, John Jed Kennedy, John L Workman, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III, Terence M Berge and Wilfredo Ruiz-Caban.
View institutional ownership trends for CONMED
.

Which institutional investors are selling CONMED stock?

CNMD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., SG Americas Securities LLC, First Trust Advisors LP, Trexquant Investment LP, Russell Investments Group Ltd., Oak Ridge Investments LLC, 6 Meridian, and Macquarie Group Ltd.. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, John Jed Kennedy, Peter K Shagory, Stanley W Peters III, and Wilfredo Ruiz-Caban.
View insider buying and selling activity for CONMED
.

Which institutional investors are buying CONMED stock?

CNMD stock was acquired by a variety of institutional investors in the last quarter, including Ceredex Value Advisors LLC, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Assenagon Asset Management S.A., AMI Asset Management Corp, Principal Financial Group Inc., New York State Common Retirement Fund, Strs Ohio, and Raymond James & Associates. Company insiders that have bought CONMED stock in the last two years include Heather L Cohen, and John L Workman.
View insider buying and selling activity for CONMED
.

How do I buy shares of CONMED?

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $86.15.

How big of a company is CONMED?

CONMED has a market capitalization of $2.46 billion and generates $955.10 million in revenue each year. The medical technology company earns $28.62 million in net income (profit) each year or $2.64 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

What is CONMED's official website?

The official website for CONMED is www.conmed.com.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.